nach oben

Erschienen in:

01.11.2003 | Ongoing Clinical Studies

A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph⁺/BCR-ABL⁺) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)

verfasst von: B. Wassmann, N. Gökbuget, U. J. Scheuring, A. Binckebanck, R. Reutzel, H. Gschaidmeier, D. Hoelzer, O. G. Ottmann, GMALL Study Group

Erschienen in: Annals of Hematology | Ausgabe 11/2003

Einloggen, um Zugang zu erhalten

Excerpt

Newly diagnosed Philadelphia chromosome-positive (Ph⁺)/BCR-ABL⁺ acute lymphoblastic leukemia (ALL) or chronic myeloid leukemia (CML) in lymphoid or bilineage blast crisis (BC) in patients older than 55 years (biological age). …

Gleißner B, Gökbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, Fonatsch C, Heyll A, Voliotis D, Beck J, Lipp T, Munzert G, Maurer J, Hoelzer D, Thiel E (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99:1536–1543CrossRefPubMed

Gökbuget N, Hoelzer D (2001) Acute lymphoblastic leukemia in adults. In: Henderson, Lister TA, Greaves MF (eds) Leukemia. W.B. Saunders, Philadelphia

Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Atta J, Brück P, Rieder H, Schoch C, Leimer L, Schwerdtfeger R, Ehninger G, Lipp T, Perz J, Stelljes M, Gschaidmeier H, Hoelzer D, Ottmann OG (2002) Imatinib mesylate (Glivec, STI571) in patients with relapsed or refractory Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ALL): extended follow-up and analysis of prognostic factors. Blood 100:87a

Gökbuget N, Hoelzer D, Arnold R (2000) Treatment of adult ALL according to the protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 14:1307–1325PubMed

Hussein KK, Dahlberg S, Head D, Waddell CC, Dabich L, Weick JK, Morrison F, Saiki JH, Metz E, Rivkin SE (1989) Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 73:57–63PubMed

Thomas X, Olteanu N, Charrin C, Lheritier V, Magaud JP, Fiere D (2001) Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol 67:73–83CrossRefPubMed

Kantarjian HM, O'Brien S, Smith TL (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547–561PubMed

Thomas X, Thiebaut A, Olteanu N, Danaila C, Charrin C, Archimbaud E, Fiere D (1998) Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther 40:119–128PubMed

Gökbuget N, de Wit M, Gerhardt A, Lipp T, Schwartz S, Sommer S, Voliotis D, Thiel E, Hoelzer D (2000) Results of a shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukemia. Blood 96 [Suppl 1]:3104a

10.

Cornelissen JJ, Carston M, Kollman C, King R, Dekker AW, Lowenberg B, Anasetti C (2001) Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 97:1572–1577CrossRefPubMed

11.

Dunlop LC, Powles R, Singhal S, Treleaven JG, Swansbury GJ, Meller S, Pinkerton CR, Horton C, Mehta J (1996) Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 17:365–369PubMed

12.

Snyder DS, Nademanee AP, O'Donnell MR, Parker PM, Stein AS, Margolin K, Somlo G, Molina A, Spielberger R, Kashyap A, Fung H, Slovak ML, Dagis A, Negrin RS, Amylon MD, Blume KG, Forman SJ (1999) Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 13:2053–2058CrossRefPubMed

13.

Martin TG, Gajewski JL (2001) Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am 15:97–120PubMed

14.

Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042PubMed

15.

Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien SG (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965–1971CrossRefPubMed

16.

Garcia-Manero G, Thomas DA (2001) Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 15:163–205PubMed

17.

Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP (2002) Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99:1860–1862CrossRefPubMed

18.

von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359:487–491CrossRefPubMed

19.

Wassmann B, Pfeifer H, Scheuring U, Binckebanck A, Gökbuget N, Atta J, Brück P, Rieder H, Schoch C, Leimer L, Schwerdtfeger R, Ehninger G, Lipp T, Ho AD, Stelljes M, Gschaidmeier H, Hoelzer D, Ottmann OG (2003) Early prediction of response in patients with relapsed or refractory Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib mesylate (Glivec) (submitted)

20.

Scheuring UJ, Pfeifer H, Wassmann B, Brück P, Atta J, Petershofen E, Gehrke B, Gschaidmeier H, Hoelzer D, Ottmann OG (2003) Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome / Bcr-Abl positive acute lymphoblastic leukemia (Ph+ALL with the ABL-tyrosine kinase inhibitor STI571 (Glivec). Blood 101:85–90CrossRefPubMed

21.

Ottmann OG, Wassmann B, Scheuring UJ, Pfeifer H, Brück P, Goekbuget N, Binckebanck A, Gehrke B, Gschaidmeier H, Hoelzer D (2002) Minimal residual disease (MRD)-triggered imatinib mesylate (Glivec, STI571) in first-line treatment of Philadelphia chromosome (Ph+) acute lymphoid leukemias: reduction of MRD levels but no induction of molecular remissions. Blood 100:85aCrossRef

22.

Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999–2007PubMed

23.

Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ (2000) Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96:3195–3199PubMed

24.

Thomas DA, Cortes J, Giles FJ, Faderl S, O'Brien S, Rios MB, Issa JP, Garcia-Manero G, Koller C, Capdeville R, Talpaz M, Kantarjian H (2001) Combination of hyper-CVAD with imatinib mesylate (STI571) for Philadelphia (Ph)-positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast phase (CML-LBP). Blood 98:802a

25.

Leis JF, Stepan DE, Curtin PT, Peng B, Ford JM, Schubach SE, Fleming WH, Druker BJ, Maziarz RT (2001) Low penetration of imatinib (STI571) into the CSF indicates the need for standard CNS prophylaxis in patients with CML lymphoid blast crisis and Philadelphia chromosome positive ALL. Blood 98:140a

26.

Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F, Grunewald K, Poewe W, Gastl G (2002) Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 117:623–625CrossRefPubMed

27.

Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S (2002) Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119:106–108CrossRefPubMed

Titel: A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)
verfasst von: B. Wassmann
N. Gökbuget
U. J. Scheuring
A. Binckebanck
R. Reutzel
H. Gschaidmeier
D. Hoelzer
O. G. Ottmann
GMALL Study Group
Publikationsdatum: 01.11.2003
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 11/2003
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-003-0728-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

15.04.2024 | Inkretinmimetika | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Fast jeder zehnte Magen bei Endoskopie noch nicht entleert

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Blutdrucksenkung per Spritze additiv zur Standardtherapie wirksam

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2003

Triplication (/αααAnti3.7) or deletion (-α3.7/) association in Argentinian β-thalassemic carriers

Severe factor X deficiency treated with heparin-added prothrombin complex concentrate

Subtotal splenectomy for the treatment of chronic lymphocytic leukemia

November 2003

Mutations of the 5′ noncoding region of the BCL-6 gene in primary bone lymphomas

Demyelination in the brain as a paraneoplastic disorder: candidates include some cases of leukemia and non-Hodgkin's lymphoma

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Fast jeder zehnte Magen bei Endoskopie noch nicht entleert

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Blutdrucksenkung per Spritze additiv zur Standardtherapie wirksam

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Innere Medizin